Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
July 29, 2024 08:25 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined...
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
January 20, 2021 15:38 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast...
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
November 25, 2020 08:12 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
August 20, 2020 08:30 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Named to ‘Most Admired Companies’ List
October 15, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...
Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
September 18, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...
Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
September 06, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21st...
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 13, 2019 08:15 ET
|
Interpace Diagnostics Group, Inc.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased Conference Call and...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
May 06, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
December 17, 2018 06:50 ET
|
Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...